随着我国人口老龄化的推进，关节炎发病人数急剧上升，已逾1亿，且数字仍在攀升。非甾体抗炎药作为治疗此病的常规药物，凭借抗炎、镇痛的功效及相对较低的不良反应率，赢得了广泛认可。在全球范围内，无论是国内还是国际药物市场，非甾体抗炎药均占据主导地位。近日，2025年11月28日，据中国国家药品监督管理局（NMPA）官网最新公示，江西施美药业股份有限公司按化药注册分类4类申报的塞来昔布胶囊获批上市，视同过评...
Source Link随着我国人口老龄化的推进，关节炎发病人数急剧上升，已逾1亿，且数字仍在攀升。非甾体抗炎药作为治疗此病的常规药物，凭借抗炎、镇痛的功效及相对较低的不良反应率，赢得了广泛认可。在全球范围内，无论是国内还是国际药物市场，非甾体抗炎药均占据主导地位。近日，2025年11月28日，据中国国家药品监督管理局（NMPA）官网最新公示，江西施美药业股份有限公司按化药注册分类4类申报的塞来昔布胶囊获批上市，视同过评...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.